302 related articles for article (PubMed ID: 37173915)
1. Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy.
Peng M; Ying Y; Zhang Z; Liu L; Wang W
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173915
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.
Tsuchikawa T; Takeuchi S; Nakamura T; Shichinohe T; Hirano S
World J Gastrointest Oncol; 2016 Nov; 8(11):786-792. PubMed ID: 27895816
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.
Dong P; Yan Y; Fan Y; Wang H; Wu D; Yang L; Zhang J; Yin X; Lv Y; Zhang J; Hou Y; Liu F; Yu X
Technol Cancer Res Treat; 2022; 21():15330338221142472. PubMed ID: 36573015
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches.
Parente P; Parcesepe P; Covelli C; Olivieri N; Remo A; Pancione M; Latiano TP; Graziano P; Maiello E; Giordano G
Gastroenterol Res Pract; 2018; 2018():7530619. PubMed ID: 30662458
[TBL] [Abstract][Full Text] [Related]
7. CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway.
Zhang L; Wang D; Li Y; Liu Y; Xie X; Wu Y; Zhou Y; Ren J; Zhang J; Zhu H; Su Z
PLoS One; 2016; 11(8):e0158529. PubMed ID: 27505247
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and tumor microenvironment of pancreatic cancer.
Liu Q; Liao Q; Zhao Y
Cancer Cell Int; 2017; 17():68. PubMed ID: 28694739
[TBL] [Abstract][Full Text] [Related]
9. Spatially confined sub-tumor microenvironments in pancreatic cancer.
Grünwald BT; Devisme A; Andrieux G; Vyas F; Aliar K; McCloskey CW; Macklin A; Jang GH; Denroche R; Romero JM; Bavi P; Bronsert P; Notta F; O'Kane G; Wilson J; Knox J; Tamblyn L; Udaskin M; Radulovich N; Fischer SE; Boerries M; Gallinger S; Kislinger T; Khokha R
Cell; 2021 Oct; 184(22):5577-5592.e18. PubMed ID: 34644529
[TBL] [Abstract][Full Text] [Related]
10. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
[TBL] [Abstract][Full Text] [Related]
11. Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment.
Shen J; Sun C; Wang Z; Chu Z; Liu C; Xu X; Xia M; Zhao M; Wang C
Int J Pharm; 2021 May; 601():120553. PubMed ID: 33794325
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
Wang S; Li Y; Xing C; Ding C; Zhang H; Chen L; You L; Dai M; Zhao Y
Am J Cancer Res; 2020; 10(7):1937-1953. PubMed ID: 32774994
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Hyung J; Lee H; Jin H; Lee S; Lee HJ; Gong G; Song TJ; Lee SS; Hwang DW; Kim SC; Jeong JH; Ryoo BY; Kim K; Yoo C
ESMO Open; 2022 Jun; 7(3):100484. PubMed ID: 35576696
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
[TBL] [Abstract][Full Text] [Related]
17. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Qian X; Hu W; Yan J
Front Immunol; 2022; 13():963533. PubMed ID: 36016946
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
19. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.
Zhang H; Ye L; Yu X; Jin K; Wu W
Front Immunol; 2022; 13():956984. PubMed ID: 36225934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
